Evaluation of ColdZyme® Mouth Spray against Common Cold in Elderly Care Personnel


Study:

Open-label, observational product evaluation study during 5 months


Subjects:

113 nursing personnel at two elderly care units and personnel at a home nursing unit. 76 subject included in the analysis.


Dosing:

According to instructions for use


Outcome measure:

Registered number of sick-days compared to the same period previous year and self reported health related quality of life and severity of experienced colds.


Study center:

Eksjö, Sweden


Background
  • Elderly care residents are more vulnerable to infections than previously thought, due to decreased immunity, having multiple chronic diseases, decreased cognitive function and the use of invasive devices (e.g. urinary catheters and enteral feeding tubes).
  • The risk of healthcare-associated infections and the spread of infection is also a reality in homecare settings of older people. Elderly care personnel are thus at risk for exposure to a variety of communicable diseases, and the risk for occupationally acquired infection is an unavoidable part of daily patient care.
  • The specific conditions of elderly care are conducive for transmitting infectious agents. Consequences for infected staff often include reduced working capacity and absence from work.

Results


  • We observed that when ColdZyme® Mouth Spray was used to reduce common cold viral infections the number of registered sick-days decreased.
  • The average number of sick-days decreased from 5.2 to 3.7 days for the 5-month period.
  • Eksjö has 282 nursing personnel employed within the elderly care unit and could theoretically reduce sick-leave among this group quite substantially
ColdZyme® Munspray


  • 63 % of those who had a cold reported the symptoms to be milder than previous colds.
  • 76 % of the subjects reported preventative use of ColdZyme.
ColdZyme® Munspray